Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study Alejandro Llanos-Cuentas, PhD, Martin Casapia, MPH, Raúl Chuquiyauri, PhD, Juan-Carlos Hinojosa, MD, Nicola Kerr, MA, Maria Rosario, PhD, Stephen Toovey, MD, Robert H Arch, PhD, Margaret A Phillips, PhD, Felix D Rozenberg, BA, Jade Bath, BA, Caroline L Ng, PhD, Annie N Cowell, MD, Elizabeth A Winzeler, PhD, David A Fidock, PhD, Mark Baker, PhD, Jörg J Möhrle, PhD, Rob Hooft van Huijsduijnen, PhD, Nathalie Gobeau, PhD, Nada Araeipour, MA, Nicole Andenmatten, PhD, Thomas Rückle, PhD, Stephan Duparc, MD The Lancet Infectious Diseases Volume 18, Issue 8, Pages 874-883 (August 2018) DOI: 10.1016/S1473-3099(18)30309-8 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 1 Trial design and patients ITT=intention-to-treat. The Lancet Infectious Diseases 2018 18, 874-883DOI: (10.1016/S1473-3099(18)30309-8) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions